Certificate of Analysis (COA)
View the laboratory certificate for this product
[ View COA ]
Ipharma Tirzpsema 34mg/pen
R 2,550.00
Product Overview Tirzepsema is a dual-peptide pre-filled pen combining Tirzepatide and Semaglutide, formulated for laboratory and research use only. Each multi-dose pen contains 34mg of active compound blend, supplied with 10 disposable injection needles for research application. Single patient/research-subject use only.
Tirzepsema is intended for use exclusively within controlled laboratory research settings. Potential research contexts include:
In vitro and in vivo studies examining GLP-1 and GIP receptor pathway activity
Comparative studies on incretin-mimetic compound behavior
Metabolic and endocrine pathway research
Peptide stability and formulation studies
This product is supplied strictly for use by qualified researchers in appropriately licensed laboratory environments. It is not intended for diagnostic, therapeutic, or human/veterinary use of any kind.
Handling & Storage
Store refrigerated at 2–8°C (36–46°F). Do not freeze.
Protect from light; keep in original packaging until use.
Once in use, follow standard cold-chain handling practices for peptide stability.
Inspect visually prior to use — do not use if solution is discolored or contains particulate matter.
Keep out of reach of children and unauthorized personnel.
Dispose of used needles in an approved sharps container in accordance with local laboratory waste regulations.
For research use only. Not for human or animal consumption.
Q: What is Tirzepsema?
A: A research-grade combination peptide formulation containing Tirzepatide and Semaglutide, intended strictly for laboratory research purposes.
Q: Is this approved for clinical or personal use?
A: No. This product is sold exclusively for research purposes and is not approved for human consumption, clinical use, or veterinary application.
Q: Is the combination of these two peptides independently studied?
A: Each compound has its own body of research individually. Research specifically evaluating their co-administration as a combined formulation is limited/not established in current published literature.
Research Overview
Tirzepatide and Semaglutide are both well-characterized incretin-mimetic compounds independently studied for their effects on glucose metabolism and appetite regulation via GLP-1 receptor pathways, with Tirzepatide additionally acting on the GIP receptor. [I'd note here rather than skip past it: research specifically on the combined co-administration of these two peptides together is not established in published literature — the individual mechanisms don't necessarily predict outcomes when combined, and I'd flag that clearly rather than imply otherwise in the copy.]
Product Features
Pre-filled multi-dose pen format for research convenience
Sterile, single-use disposable needles included (x10)
Dual receptor-pathway compound blend
For laboratory/research use only — not for human or veterinary use
